Oncology (Medical)

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Evaluate Immune and Hematopoietic Cell Assessment in Clonal B Cell Conditions

   Rochester, Minn.

   The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) in comparison to age-matched healthy control (HC) donors.

2. A Study to Evaluate Maximizing Anti-PD-1 Therapy By Monitoring T Cell Responses In Melanoma, Lung and Other Cancer Types

   Rochester, Minn.

   The purpose of this study is to monitor T cell responses from patients with advanced cancer who are being treated with an anti-PD (programmed death)-1 monoclonal antibody, and compare them with clinical outcomes.

3. A Study to Explore if it is Possible to Successfully Obtain Optical Coherence Tomography (OCT) Imaging and Data While Patients Undergo Brain Surgery

   Jacksonville, Fla.

   The goal of this study is to investigate the feasibility of successfully obtaining intra-operative OCT imaging and data during standard brain surgery.

4. A Study of the Impact of the Terminology Used to Identify Papillary Thyroid Cancer on the Treatment Options Chosen by Patients

   Rochester, Minn.

   The purpose of this study is to explore how using different terms (with or without the word cancer) to identify papillary thyroid cancer might affect the decisions patients would make about treatment.

5. Tissue and Blood Registry for Individuals with Liver and Biliary Tumors

   Jacksonville, Fla.

   This study will collect and store samples of tissue and blood for current and future research studies on Liver and Biliary Tumors.

6. Assessing Breast Cancer Risk Perception in Hispanic, Black, and Black Hispanic Women

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to understand how women of color from diverse racial and ethnic backgrounds conceptualize their current and lifetime risk for breast cancer (BC) and to identify which risk factors most resonate with perceptions of BC risk.

    

7. A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

   Rochester, Minn.

   The primary objectives of this study are to determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of selumetinib + vinblastine for children with progressive or recurrent LGGs, and to determine if selumetinib + vinblastine will lead to improved event-free survival (EFS) outcome compared with selumetinib alone for children with progressive or recurrent LGGs.

8. A Study to Establish a Living Breast Organoid Biobank for Translational Research

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   Researchers at Mayo Clinic are developing a Biobank of adult stem cell-rich breast organoids, a new research resource to facilitate normal and cancer stem cell research. Subjects in the Biobank will provide samples of excess breast tissue, complete a health questionnaire, and allow access to medical records now and in the future. The Biobank serves as a library for researchers; instead of having to look for volunteers for each new project, researchers can use samples from the Biobank as well as share information already collected.

9. Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) in Patients with Metastatic Pancreatic Adenocarcinoma

   Jacksonville, Fla.

   The purpose of this study is to assess the safety of a specific treatment regimen (protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN)) combined with a device called Tumor Treatment Fields (TTF) in preventing tumor growth in paitents with recurrent recurrent and/or metastatic pancreatic cancer (met-PC).

10. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter Transformation

    Rochester, Minn.

    The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter’s transformation, and what doses of these drugs are safe for people to take. We also want to learn about the side effects of this combination. All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung cancers including  non-small cell lung cancer and small cell lung cancer. Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn’t approved by the U.S. Food and Drug Administration (FDA). However, the FDA has allowed the use of this drug in this research study.